INTRODUCTION
COVID-19 has rapidly spread worldwide, with thousands of new cases diagnosed daily, particularly during waves of contamination [1]. The severity of the disease has decreased considerably due to the effectiveness of the currently available vaccine, and half of the world’s population has been fully vaccinated [2]. However, the initial pandemic scenario caused a considerable societal, economic and health burden resulting in millions of deaths and billions of dollars spent on treating and managing COVID-19 [3].

SARS-CoV-2 is primarily a respiratory virus with clinical manifestations similar to pneumonia, such as coughing, dyspnoea and fever [4]. While a considerable proportion of the infected population remains asymptomatic or develops mild symptoms [5], a large portion of people with COVID-19 did suffer from moderate to severe respiratory failure due to the development of hypoxia, as well as additional systemic complications that required hospital admission, especially in intensive care units (ICUs) [6]. Other forms of oxygen support that offered higher fractions of inspired oxygen, such as the high-flow nasal cannula (HFNC), were rapidly considered as treatment options due to the possibility of patient management outside the ICUs [7], therefore minimizing more severe outcomes, such as intubation [8].

The “usual” challenge during the COVID-19 pandemic
The peak stage of the pandemic was marked by hospitals operating at maximal capacity and shortages in qualified health care staff and medical equipment, specifically mechanical ventilators [9]. As a result, many ad hoc ICUs [10] and medical wards [11] were created worldwide. The overall purpose of these units was to manage respiratory distress in situ, therefore reducing the need for ICU transfer [10]. In addition, a number of wards were rapidly equipped with mechanical ventilators and other types of equipment to provide oxygen support, such as the HFNC [11].

HFNC therapy: the basis for the respiratory rate-oxygenation (ROX) index
HFNC therapy is a noninvasive oxygen therapy that provides a heated and humidified high flow of blended oxygen using a single circuit and a nasal prong. The flow can be adjusted between 10 and 60 litres per minute (L/min), with a fraction of inspired oxygen (FiO₂) ranging from 0.21 to 1.0. Some physiological benefits of this therapy include oxygenation improvement, reduction of anatomical dead space and the potential provision of positive end-expiratory pressure (PEEP), helping to reduce the work of breathing [12].

The HFNC has been used mainly to avoid more invasive forms of oxygen therapy, such as mechanical ventilation [13]. This therapy has been used to treat a variety of subjects of different age ranges, from neonates to adults, with various respiratory conditions, including acute hypoxemic respiratory failure to hypercapnic lung failure, given the PEEP-like effect [14]. Although reduction in the work of breathing has been reported, limited evidence is available regarding clinical outcomes among patients with hypercapnic failure [15], and caution has been advised to avoid the deterioration of respiratory drive at higher oxygen concentrations, particularly among individuals with chronic obstructive pulmonary disease [14]. The HFNC has also been able to treat respiratory failure in trauma and immunosuppressed patients, provide comfort in palliative care and provide oxygen support during specific procedures, such as bronchoscopy [14].

The respiratory rate-oxygenation (ROX) index is defined as the ratio of peripheral oxygen saturation/FiO₂ to respiratory rate [16]:

\[
\text{ROX} = \frac{\text{O}_2\text{Sat}}{\text{FiO}_2 \times \text{RR}}
\]

Roca et al. [16, 17] created it to predict the need for mechanical ventilation among patients with pneumonia and acute respiratory failure treated with HFNC. The authors showed that a ROX index consistently equal to or greater than 4.88 measured 2 h, 6 h and 12 h after HFNC therapy indicated a lower risk for needing mechanical ventilation [16, 17].

The ROX index has been closely used in conjunction with the HFNC, serving as a guiding parameter to help monitor this therapy’s success or failure. Since the start of the COVID-19 pandemic, there has been a number of studies corroborating the ROX index as a valuable predictor of the success or failure of the HFNC therapy among COVID-19 patients [18], as well as non–COVID-19 patients [19]. Its predictive validity in detecting respiratory-related adverse events has surpassed...
The ROX index has been used to identify patients at risk for poor health outcomes, such as sepsis [29], and mechanical ventilation [30]. Lee et al. [29] showed that a ROX index of ≥ 10 at admission in an emergency department was used as an independent prognostic factor for 28-day mortality among patients with sepsis or septic shock. The authors suggested that the ROX index can potentially be used as a prognostic marker [29].

Similarly, Ahn et al. [30] examined the predictive value of the ROX index in requiring mechanical ventilation among patients with sepsis admitted to the emergency department. Results showed that the ROX index was significantly lower (value of 4) among patients who required mechanical ventilation compared to those who did not require it (value of 10), with a sensitivity of 75% and a specificity of 81.6%. The index was independently associated with the use of mechanical ventilation within 24 h in the emergency department [30].

A helpful tool for patients with sepsis in the emergency department

The ROX index can potentially be used as a prognostic marker [29]. It has been shown that the ROX index ≤ 3.85 12 h after HFNC initiation strongly predicts invasive mechanical ventilation among COVID-19 patients. The index was, in fact, included in the routine monitoring in the northern California health delivery system to optimize inpatient care [23]. Suliman et al. [24] also validated the ROX index, particularly on day 1 (at admission), as a reliable tool for predicting the risk of intubation in COVID-19 patients using the HFNC. Although a higher cutoff value was reported as ≥ 25.26 on day 1, the authors acknowledged that milder cases of COVID-19 were considered, increasing the index's value [24].

The ROX index has shown to be a practical instrument. It has been used in a variety of health settings during the COVID-19 pandemic and its potential future applicability.

During the COVID-19 pandemic

Reducing the risk of intubation with the HFNC therapy

Delaying time for intubation, particularly among COVID-19 patients, has been associated with several negative physiological and clinical outcomes, such as higher mortality and higher death space ratio [22]. Therefore, it is paramount to identify when it is necessary to discontinue noninvasive oxygen therapy and initiate mechanical ventilation. It has been shown that the ROX index ≤ 3.85 h after HFNC initiation strongly predicts invasive mechanical ventilation among COVID-19 patients. The index was, in fact, included in the routine monitoring in the northern California health delivery system to optimize inpatient care [23]. Suliman et al. [24] also validated the ROX index, particularly on day 1 (at admission), as a reliable tool for predicting the risk of intubation in COVID-19 patients using the HFNC. Although a higher cutoff value was reported as ≥ 25.26 on day 1, the authors acknowledged that milder cases of COVID-19 were considered, increasing the index's value [24].

The ROX index was assessed as a prognostic indicator among COVID-19 patients who failed noninvasive ventilation (HFNC or continuous positive airway pressure, CPAP) and required mechanical ventilation. Results showed a median ROX of > 7.0 predicted ICU survival [25]. The ROX index showed acceptable accuracy in predicting hospitalization and mortality rates among COVID-19 patients admitted to the emergency department. Gianstefani et al. [26] showed that a ROX index value of < 25.7 was associated with increased hospitalization time, while a value of < 22.3 was associated with a higher 30-day mortality rate.

Triage of COVID-19 patients with dyspnoea

The ROX index has been a valuable tool in assisting the emergency team in triaging COVID-19 patients with dyspnoea without confirmed respiratory distress but at risk for developing acute respiratory distress syndrome (ARDS) [27]. Zaboli et al. [27] assessed the ROX index during triage (at admission) and compared it to the incidence of ARDS and to the risk of intubation 72 h after triage. Patients who developed ARDS had a lower average median ROX index (value of 13.1) compared to those who did not develop ARDS (value of 25.2). Similarly, lower median ROX values were reported among those who underwent intubation procedure 72 h after triage (value of 15.3) compared to those who did not require intubation (value of 22.2). The study showed that this index could serve as a screening tool for predicting disease progression and risk of intubation.

Predicting CPAP failure

The ROX index was assessed as a prognostic indicator among COVID-19 patients receiving CPAP in a respiratory ward [28]. Results showed that ROX index values of > 6.32 pre-CPAP and > 7.77 after the first 24 h of CPAP therapy were indicative of successful therapy weaning in > 80% of cases [28].

The ROX index applicability beyond the context of the COVID-19 pandemic

A helpful tool for patients with sepsis in the emergency department

The ROX index has been used to identify patients at risk for poor health outcomes, such as sepsis [29] and mechanical ventilation [30]. Lee et al. [29] showed that a ROX index of ≥ 10 at admission in an emergency department was used as an independent prognostic factor for 28-day mortality among patients with sepsis or septic shock. The authors suggested that the ROX index can potentially be used as a prognostic marker [29].

Similarly, Ahn et al. [30] examined the predictive value of the ROX index in requiring mechanical ventilation among patients with sepsis admitted to the emergency department. Results showed that the ROX index was significantly lower (value of 4) among patients who required mechanical ventilation compared to those who did not require it (value of 10), with a sensitivity of 75% and a specificity of 81.6%. The index was independently associated with the use of mechanical ventilation within 24 h in the emergency department [30].

Predicting successful noninvasive ventilation among thoracic trauma patients

The index has also shown to be effective in predicting the successful use of noninvasive oxygen therapy (via standard oxygen therapy, HFNC or noninvasive ventilation) and, therefore, not requiring mechanical ventilation in thoracic trauma patients. A median ROX index of ≥ 12.85 in the first 24 h after the initiation of noninvasive oxygen therapy was a successful predictor of not requiring mechanical ventilation for the next seven days after thoracic trauma [31].

Is there an ideal cut-off value for the ROX index?

Although an ideal cut-off value for therapy success has not been reached, systematic reviews have provided a narrower range of values with adequate predictive capacity for successful HFNC weaning. Junhai et al. [19] have found acceptable specificity (0.72 (95% CI 0.65–0.78)) but low sensitivity (0.67 (95% CI 0.57–0.76)). In a subgroup analysis of COVID-19 patients only, the predictive value was moderate (pooled sensitivity and specificity of 0.71 (95% CI 0.56–0.82) and 0.73 (95% CI 0.63–0.81), respectively), and a cut-off value of > 5 in predicting HFNC failure was reported (sensitivity and specificity 0.59 (95% CI 0.54–0.65) and 0.83 (95% CI 0.79–0.86), respectively). Zhou et al. [32] showed that among patients with acute hypoxemic respiratory failure related to COVID-19, a ROX value between 4.2 and 5.4 measured either after 6 h or between 6 and 12 h after HFNC therapy initiation has shown to be a good predictor of therapy success (pooled sensitivity 0.71 (95% CI 0.64–0.78) and pooled specificity 0.78 (95% CI 0.70–0.84)).

Some limitations of the ROX index have been identified, which may influence consensus towards an ideal cut-off value. First, a variety of pathologies have been assessed using the ROX index, including sepsis [29], COVID-19, acute respiratory failure and pneumonia [19]. Second, different types of noninvasive oxygen therapy have been studied, including HFNC [32] and conventional oxygen therapy [31]. Third, a lack of regularity regarding measurement intervals has been reported, such as the first 6 h of therapy, the first 6 to 12 h [32], and the first day of admission [24]. Fourth, small sample sizes and a lack of high methodological quality studies have been reported [32]. Future studies should address these limitations to provide greater respiratory monitoring using this index.

CONCLUSION

The ROX index has shown to be a practical instrument. It has been used in a variety of health settings during the COVID-19 pandemic and has served to foster best practices related to the use of HFNC therapy. Its ability to predict health-related outcomes has been amplified beyond the COVID-19 pandemic, assisting the health care team in identifying patients at risk for potentially unfavourable respiratory outcomes and guiding the decision-making process. Its applicability has warranted further research.

DISCLOSURES

Contributors

All authors contributed to the conception or design of the work and the acquisition, analysis or interpretation of the data. All authors were involved in drafting and commenting on the paper and have approved the final version.
Funding
This study did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Competing interests
All authors have completed the ICMJE uniform disclosure form and declare no conflict of interest.

Ethical approval
Not required for this article type.

REFERENCES
1. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19. who.int (Accessed September 01, 2022)
2. Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19). Our World in Data; 2020
3. Zhao J, Jin H, Li X, et al. Disease burden attributable to the first wave of COVID-19 in China and the effect of timing on the cost-effectiveness of movement restriction policies. Value Health 2021;24(5):615–24. doi: 10.1016/j.jval.2020.12.009.
4. CDC. COVID-19 and your health. Centers for Disease Control and Prevention; 2020.
5. McArthur L, Sakhivel D, Ataide R, Chan F, Richards JS, Narh CA. Review of burden, clinical definitions, and management of COVID-19 cases. Am J Trop Med Hyg 2020;103(2):625–38. doi: 10.4269/ ajtmh.200564.
6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5.
7. Jackson JA, Spilman SK, Kingery LK, et al. Implementation of high-flow nasal oxygen therapy outside the intensive care setting. Respir Care 2021;66(3):357–65. doi: 10.4187/respcare.07960.
8. Alkouh R, El Rhalete A, Manal M, et al. High-flow nasal oxygen therapy decrease the risk of mortality and the use of invasive mechanical ventilation in patients with severe SARS-CoV-2 pneumonia: A retrospective and comparative study of 265 cases. Ann Med Surg 2022;74:103230. doi: 10.1016/j.amsu.2021.103230.
9. BTS preparing for the capacity challenges posed by COVID-19. 2020. Available at: https://www.scrm.co.uk/2020/04/bts-preparing-for-the-capacity-challenges-posed-by-covid-19/files/7986/bts-preparing-for-the-capacity-challenges-posed-by-covid-19.html (Accessed April 08, 2022)
10. Grisetti GR, Piccinin M. COVID-19 pandemic in ICU. Limited resources for many patients: approaches and criteria for triaging. Minerva Anestesiol 2021 Dec;87(12):1367–79. doi: 10.23736/ S0375-9393.21.15736-0.
11. Calligaro GL, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: a multi-centre prospective observational study. EClinicalMedicine 2020;28:100570. doi: 10.1016/j.eclinm.2020.100570.
12. Mauri T, Wang YM, Dalla Corte F, Corcione N, Spinelli E, Pesenti A. Nasal high flow: physiology, efficacy and safety in the acute care setting, a narrative review. Open Access Emerg Med 2019;11:109–20. doi: 10.2147/OAEM.S180197.
13. Franco C, Facciolongo N, Tonelli R, et al. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. Eur Respir J 2020;56(5):2002130. doi: 10.1183/13993003.02130-2020.
14. Boccatonda A, Geoff P. High-flow nasal cannula oxygenation utilization in respiratory failure. Eur J Intern Med 2019;64:10–14. doi: 10.1016/j.ejim.2019.04.010.
15. Pisani L, Astuto M, Prediletto I, Longhini F. High flow through nasal cannula in exacerbated COPD patients: a systematic review. Pulmonology 2019;25(6):348–54. doi: 10.1016/j.pulmoe.2019.08.001.
16. Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in patients with hypoxic respiratory failure: the utility of the ROX index. J Crit Care 2016;35:200–5. doi: 10.1016/j.jccr.2016.05.022.
17. Roca O, Caralt B, Messika J, et al. An index combining respiratory ratio and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med 2019;199(11):1366–76. doi: 10.1164/rccm.201810-2017OC.
18. Prakash J, Bhattacharya PK, Yadav AK, Kumar A, Tudu LC, Prasad K. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. J Crit Care 2021;66:102–8. doi: 10.1016/j.jccr.2021.08.012.
19. Junhaze Y, Beibei C, Li L. The value of ROX index in predicting the outcome of high flow nasal cannula: a systematic review and meta-analysis. Respir Res 2022;23(1):33. doi: 10.1186/s12931-022-01951-9.
20. Prower E, Grant D, Bisaqara A, et al. The ROX index has greater predictive validity than NEWS2 for deterioration in COVID-19. EClinicalMedicine 2021;15:100828. doi: 10.1016/j.eclinm.2021.100828.
21. Hu M, Zhou Q, Zheng R, et al. Application of high-flow nasal cannula in hypoxic patients with COVID-19: a retrospective cohort study. BMC Pulm Med 2020;20(1):324. doi: 10.1186/s12890-020-01354-w.
22. Bavishi AA, Mylaganam RJ, Agarwal R, Avery RJ, Curticca MJ. Timing of intubation in coronavirus disease 2019: a study of ventilator mechanics, imaging, findings, and outcomes. Crit Care Explor 2021;3(6):e0415. doi: 10.1097/CCE.0000000000000415.
23. Myers LC, Mark D, Ley B, et al. Validation of respiratory rate-oxygenation index in patients with COVID-19-related respiratory failure. Crit Care Med 2022;50(7):e638–42. doi: 10.1097/CCM.0000000000005474.
24. Saliman LA, Abdelgawad TT, Farrag NS, Abdelwahab HW. Validation of rox index in prediction of risk of intubation in patients with covid-19 pneumonia. Adv Respir Med 2021;89(1):1–7. doi: 10.5631/ARM.a2020.0176.
25. Leszek A, Wozniak H, Giudicelli-Bailly A, et al. Early measurement of ROX index can be a useful tool to predict the need for intubation in patients with COVID-19 pneumonia. Healthcare 2022;10(2):365. doi: 10.3390/healthcare10020365.
26. Gianstefani A, Farina G, Salvatore V, et al. Role of ROX index in the first assessment of COVID-19 patients in the emergency department. Intern Emerg Med 2021;16(7):1959–65. doi: 10.1007/s11739-021-02675-2.
27. Zaboli A, Ausserhofer D, Feifer N, et al. The ROX index can be a useful tool for the triage evaluation of COVID-19 patients with dyspnoea. J Adv Nurs 2021;77(8):1361–9. doi: 10.1111/jan.14848.
28. Youssaf A, Gotlibh D, Auger A, Pescov P, Konda S. An observational longitudinal study of the use of ROX index to predict treatment failure in patients receiving continuous positive airway pressure for COVID-19. Health Sci Rep 2022;5(1):e482. doi: 10.1002/hsr2.482.
29. Lee CU, Jo YH, Lee JH, et al. The index of oxygenation to respiratory rate as a prognostic factor for mortality in sepsis. Am J Emerg Med 2021;45:426–32. doi: 10.1016/j.ajem.2020.09.052.
30. Ahn S, Park J, Song J, Kim J, Cho H, Moon S. Association of ROX index with mechanical ventilator use in sepsis patients in the emergency department. J Clin Med 2022;11(2):365. doi: 10.3390/jcm11020365.
31. Cornillon A, Balbo J, Coffinet J, et al. The ROX index as a predictor of standard oxygen therapy outcomes in thoracic trauma. Scand J Trauma Resusc Emerg Med 2021;29(1):81. doi: 10.1186/s13049-021-00876-4.
32. Zhou X, Liu J, Pan J, Xu Z, Xu J. The ROX index as a predictor of high-flow nasal cannula outcome in pneumonia patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. BMC Pulm Med 2022;22(1):121. doi: 10.1186/s12890-022-0394-2.